ClinicalTrials.gg
CompletedNCT00742248Updated Jul 31, 2020

Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Formoterol and Formoterol in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-07-31.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
55th of 89
54 · median 120
Started
2004
with 1 other
Phase 2
12 of 89
none open now
Registered
23rd of 89
by date
Lead sponsor
11 of 89
Chiesi Farmaceutici S.p.A.

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 55th largest by enrollment, is one of 2 that started in 2004, is one of 12 in phase 2, and was the 23rd registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate equivalent efficacy between two different formulations of formoterol (pMDI using HFA-134 propellant and dry powder) on lung function in adult patients with partially reversible COPD.

Read the detailed description

The present study is aimed at investigating the effect of a single 12 µg dose and of a short 7-day course of formoterol HFA-134a, compared to a formoterol DPI formulation, on specific parameters that are appropriate for assessment of single-dose and short-term effects on COPD.

This study has been designed to assess the efficacy with the traditional use of FEV1. Furthermore, the use of other efficacy parameters such as changes in exertion tolerance and dyspnoea, dynamic and static volumes measured using a whole body plethysmograph, such as TLC, RV, IC and airways conductance sGAW has been included.

This is a double blind, double dummy, multicentre, randomised, placebo-controlled, cross-over study in at least 36 adult patients with partially reversible COPD. The two test treatments and placebo will be administered in a single and repeated (twice daily for 7 days) dose cycle (with a minimum 2 days and maximum 7 days of wash-out between each cycle).

Seven clinic visits in total will take place at the start and end of the run-in period, and at the first and at the last dose of each treatment cycle (with placebo and the two active treatment tests), with an acceptable variation of a maximum of ± 1 day in respect of the scheduled days at the end of each treatment cycle (i.e. treatment with placebo or active drug may range between 6 and 8 days).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of either sex aged > 40 years.
  • Clinical diagnosis of partially reversible , with or without chronic symptoms, in line with the following recommendations of the National Heart Lung and Blood Institute/World Health Organisation (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD) (22):
  • Post-bronchodilator ≥ 30% and \< 80% of the predicted normal values, and at least 0.7 L (if less than 0.7 L, FEV1 must be ≥ 40% of predicted normal value)
  • FEV1/FVC ratio \< 70%.
  • Positive partial response to the reversibility test in the screening visit, defined as an increase from baseline value of at least 5% of the percentage of predicted normal value (post-dosing minus pre-dosing/pre-dosing x 100) in the FEV1 measurement 30 minutes following 4 puffs (4 x 100 µg) of inhaled salbutamol pMDI.
  • Current or past tobacco heavy smoking habits (defined as smoking for > 20 pack years, where 1 pack year = 20 cigarettes/day for 1 year or equivalent).
  • A cooperative attitude and ability to be trained to use correctly the pMDI and the AerolizerTM inhaler.
  • Written obtained.

Exclusion criteria

Exclusion Criteria:

  • Evidence of exacerbation and/or symptomatic infection of the airways in the previous 4 weeks requiring antibiotic therapy.
  • History of disease whose sequelae and/or treatments can interfere with the results of the present study.
  • Presence of asthma.
  • Evidence of bronchiectases.
  • History of inadequate cardiac, hepatic and/or renal function.
  • History of coronary artery disease, myocardial infarction, cerebrovascular disease, cardiac arrhythmias, severe hypertension and diabetes mellitus.
  • Other haemodynamic relevant rhythm disturbances (including atrial flutter or atrial fibrillation with ventricular response, bradycardia (≤ 55 bpm), evidence of atrial-ventricular (AV) block on of more than 1st degree.
  • History of percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG).
  • Patients with a serum potassium value ≤ 3.5 mEq/L and/or serum glucose value ≥ 140 mg/dL.
  • Patients with an abnormal value in the ECG test, defined as > 450 msec in males or > 470 msec in females.
  • Evidence of posture and gait disturbances, or impairment of limb coordination due to any cause.
  • Patients taking oral in the last month prior to study entry.
  • Patients taking inhaled long-acting β2-agonists or anticholinergics in the last 48 hours.
  • Patients already taking inhaled corticosteroids (including nasal), sodium cromoglycate and nedocromil sodium, leukotriene antagonists, xanthyne derivatives, mucolytics, antitussives for whom the dose has been changed in the last month before study entry or is likely to change during the total study period.
  • History of to sympathomimetic drugs.
  • Patients taking β-antagonists, tricyclic antidepressants or monoamine oxidase inhibitors (MAOI).
  • Pregnant or lactating females or females at risk of pregnancy, i.e. those not demonstrating adequate (i.e. barrier methods, intrauterine devices, hormonal treatment or sterilization). A pregnancy test is recommended - Patients with a post-bronchodilator \< 0.7 L and with a predicted normal FEV1 \< 40%.
  • Patients requiring long-term oxygen therapy.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Active comparator
    A

    Formoterol pMDI

    Drug: Formoterol · Drug: Placebo

  • Active comparator
    B

    Formoterol dry powder

    Drug: Formoterol · Drug: Placebo

  • Placebo comparator
    C

    Placebo pMDI DPI

    Drug: Placebo

Interventions

  • pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening

    Also known as: Atimos

  • DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening

    Also known as: Foradil

  • DrugPlacebo

    Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening

06

What researchers measure

Primary outcomes

  1. FEV1 area under the curve (AUC) standardized for time

    Time frame: 4 hours following the morning dose of study medication at the first visit of each treatment cycle

Secondary outcomes

  1. Clinical equivalence in terms of FEV1 area under the curve (AUC) standardized for time

    Time frame: 4 hours

07

Study locations

1 site
  • "Centro Dipartimentale di Fisiopatologia Respiratoria", University of Genoa
    Genova, 16132, Italy
08

References and documents

Publications

  • Brusasco V, Canonica GW, Dal Negro R, Scano G, Paggiaro P, Fabbri LM, Barisione G, D'Amato G, Varoli G, Baroffio M, Milanese M, Mereu C, Crimi E. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD. J Aerosol Med Pulm Drug Deliv. 2011 Oct;24(5):235-43. doi: 10.1089/jamp.2010.0862. Epub 2011 Jun 20. PubMed 21689019 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of May 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2008
First posted
Aug 27, 2008
Start
Sep 2004
Primary completionActual
May 2005
CompletionActual
May 2005
Last update
Jul 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00742248
Collaborators
Vito Brusasco "Centro Dipartimentale di Fisiopatologia Respiratoria", University of Genoa, Italy (Co-ordinating centre), Giovanni Barisione "Unità Operativa di Medicina Preventiva e del Lavoro, Laboratorio di Fisiopatologia Respiratoria", S. Martino Hospital, Genoa, Italy, Universita degli Studi di Genova, Cardarelli Hospital, Roberto Dal Negro "Unità Operativa di Pneumologia", Hospital of Bussolengo (Verona), Italy, University of Modena and Reggio Emilia, Carlo Mereu "Struttura complessa di Pneumologia", S. Corona Hospital, Pietra Ligure (Savona), Italy, University of Pisa, Fondazione Don Carlo Gnocchi Onlus
First posted
Aug 27, 2008
Start date
Sep 2004
Primary completion
May 2005
Completion
May 2005
Last update
Jul 31, 2020

Study contacts

Giovanni Barisione, MD
principal investigator · "Unità Operativa di Medicina Preventiva e del Lavoro, Laboratorio di Fisiopatologia Respiratoria", S. Martino Hospital, Genoa, Italy
Giorgio Canonica, MD
principal investigator · 3) "Clinica di Malattie dell'Apparato Respiratorio e Allergologia, Dipartimento di Medicina Interna", University of Genoa, Italy
Gennaro D'Amato, MD
principal investigator · 'Unita' di Pneumologia e Allergologia, Dipartimento di Medicina Respiratoria', A. Cardarelli Hospital, Naples, Italy
Roberto Dal Negro, MD
principal investigator · 5) "Unità Operativa di Pneumologia", Hospital of Bussolengo (Verona), Italy
Leonardo Fabbri, MD
principal investigator · "Clinica di Malattie dell'Apparato Respiratorio", University of Modena, Italy
Carlo Mereu, MD
principal investigator · "Struttura complessa di Pneumologia", S. Corona Hospital, Pietra Ligure (Savona), Italy
Pierluigi Paggiaro, MD
principal investigator · "Servizio di Fisiopatologia Respiratoria, Dipartimento Cardiotoracico", University of Pisa, Italy
Giorgio Scano, MD
principal investigator · "Unità Operativa di Riabilitazione Respiratoria, Fondazione Don Carlo Gnocchi ONLUS", Pozzolatico (FI), Italy
Vito Brusasco, MD, PhD
study director · "Centro Dipartimentale di Fisiopatologia Respiratoria", University of Genoa, Italy (Co-ordinating centre)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion